Effects of (R,S)/(S,R)-4,5-bis(2-chloro-4-hydroxyphenyl)-2-imidazolines and (R,S)/(S,R)-2,3-bis(2-chloro-4-hydroxyphenyl)piperazines on ER alpha levels and transcriptional activity in MCF-7 cells
Laïos, Ioanna; Cleeren, Anny; Leclercq, Guyet al.
2007 • In Biochemical Pharmacology, 74 (7), p. 1029-1038
[en] 4,5-Diaryl-2-imidazolines (Im(s)) and 2,3-diarylpiperazines (Pip(s)) belong to the type II class of estrogens. These compounds enhance ERalpha-mediated transcription of ERE-driven reporter genes in MCF-7 cells but do not compete with [(3)H]estradiol (E(2)) for receptor binding, because of distinct anchoring modes. The present study examined whether the estrogenic action of Im(s) and Pip(s) is associated with a down regulation of ERalpha, as reported for conventional agonists. Im and Pip derivatives displaying a large spectrum of activities in three distinct ERE-dependent transactivation systems were selected for that purpose. ERalpha immunostaining as well as Western blotting analysis revealed that both classes of compounds down regulated ERalpha with an efficiency closely related to their transactivation potency. MG-132 abrogated this down regulation, pointing to a proteasomal degradation process. Im(s) and Pip(s) with strong transactivation potency also altered [(3)H]E(2) binding parameters, leading to a progressive decrease of cellular estrogen binding capacity. This property occurred largely before ERalpha down regulation and persisted even in presence of MG-132, indicating that it did not result from ERalpha breakdown but rather from a conformational change of the receptor. The additional finding that the most active agonist tested in this study enhanced the capacity of a purified ERalpha recombinant to recruit LxxLL co-activators, while its inactive counterpart failed to do so confirmed this hypothesis. Altogether, our data indicate that the association of Im(s) and Pip(s) with ERalpha elicits similar responses to conventional agonists, even if they interact with distinct residues of the binding pocket.
Disciplines :
Immunology & infectious disease Oncology
Author, co-author :
Laïos, Ioanna
Cleeren, Anny
Leclercq, Guy
Nonclercq, Denis ; Université de Mons > Faculté de Médecine et de Pharmacie > Service d'Histologie
Laurent, Guy ; Université de Mons > Faculté de Médecine et de Pharmacie > Histologie
Schlenk, Miriam
Wellner, Anja
Gust, Ronald
Language :
English
Title :
Effects of (R,S)/(S,R)-4,5-bis(2-chloro-4-hydroxyphenyl)-2-imidazolines and (R,S)/(S,R)-2,3-bis(2-chloro-4-hydroxyphenyl)piperazines on ER alpha levels and transcriptional activity in MCF-7 cells
Publication date :
01 October 2007
Journal title :
Biochemical Pharmacology
ISSN :
0006-2952
Publisher :
Elsevier, Netherlands
Volume :
74
Issue :
7
Pages :
1029-1038
Peer reviewed :
Peer Reviewed verified by ORBi
Research unit :
M118 - Histologie
Research institute :
R550 - Institut des Sciences et Technologies de la Santé
Alarid E.T. Lives and times of nuclear receptors. Mol Endocrinol 20 (2006) 1972-1981
Leclercq G., Lacroix M., Laïos I., and Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr Cancer Drug Targets 6 (2006) 39-64
Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
Nawaz Z., and O'Malley B.W. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription?. Mol Endocrinol 18 (2004) 493-499
Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11 (2003) 695-707
McGuire W.L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5 (1978) 428-433
Borras M., Hardy L., Lempereur F., el Khissiin A.H., Legros N., Gol-Winkler R., et al. Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression. J Steroid Biochem Mol Biol 48 (1994) 325-336
Laïos I., Journe F., Nonclercq D., Vidal D.S., Toillon R.A., Laurent G., et al. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J Steroid Biochem Mol Biol 94 (2005) 347-359
Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
Kong E.H., Pike A.C., and Hubbard R.E. Structure and mechanism of the oestrogen receptor. Biochem Soc Trans 31 (2003) 56-59
Kekenes-Huskey P.M., Muegge I., von Rauch M., Gust R., and Knapp E.W. A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores. Bioorg Med Chem 12 (2004) 6527-6537
Jordan V.C., Schafer J.M., Levenson A.S., Liu H., Pease K.M., Simons L.A., et al. Molecular classification of estrogens. Cancer Res 61 (2001) 6619-6623
Gust R., Keilitz R., and Schmidt K. Investigations of new lead structures for the design of selective estrogen receptor modulators. J Med Chem 44 (2001) 1963-1970
Gust R., Keilitz R., Schmidt K., and von Rauch M. (4R,5S)/(4S,5R)-4,5-Bis(4-hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode. J Med Chem 45 (2002) 3356-3365
Gust R., Keilitz R., and Schmidt K. Synthesis, structural evaluation, and estrogen receptor interaction of 2,3-diarylpiperazines. J Med Chem 45 (2002) 2325-2337
von Rauch M., Schlenk M., and Gust R. Effects of C2-alkylation, N-alkylation, and N,N′-dialkylation on the stability and estrogen receptor interaction of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines. J Med Chem 47 (2004) 915-927
Soule H.D., Vazguez J., Long A., Albert S., and Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51 (1973) 1409-1416
Levenson A.S., and Jordan V.C. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 57 (1997) 3071-3078
Hafner F., Holler E., and von Angerer E. Effect of growth factors on estrogen receptor mediated gene expression. J Steroid Biochem Mol Biol 58 (1996) 385-393
Pons M., Gagne D., Nicolas J.C., and Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 9 (1990) 450-459
Tamrazi A., Carlson K.E., Rodriguez A.L., and Katzenellenbogen J.A. Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation. Mol Endocrinol 19 (2005) 1516-1528
El Khissiin A., Journe F., Laios I., Seo H.S., and Leclercq G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids 65 (2000) 903-913
Seo H.S., DeNardo D.G., Jacquot Y., Laïos I., Vidal Salazar D., Rojas Zambrana C., et al. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat 99 (2006) 121-134
Gee A.C., Carlson K.E., Martini P.G., Katzenellenbogen B.S., and Katzenellenbogen J.A. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol Endocrinol 13 (1999) 1912-1923
El khissiin A., and Leclercq G. Exchange of bound estrogens and antiestrogens in MCF-7 cells: evidence for ligand-induced stable configurations of the estrogen receptor. Steroids 63 (1998) 565-574
Fliss A.E., Benzeno S., Rao J., and Caplan A.J. Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol 72 (2000) 223-230
Leclercq G., Legros N., and Piccart M.J. Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment. J Steroid Biochem Mol Biol 41 (1992) 545-552
Gallo D., Jacquemotte F., Cleeren A., Laios I., Hadiy S., Rowlands M.G., et al. Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha. Mol Cell Endocrinol 268 (2007) 37-49
Gallo D., Jacquot Y., Cleeren A., Jacquemotte F., Laios I., Laurent G., et al. Molecular basis of agonistic activity of ERa17p, a synthetic peptide corresponding to a sequence located at the N-terminal part of the estrogen receptor α ligand binding domain. Lett Drug Des Discov 4 (2007) 346-355
Jacquot Y., Laïos I., Cleeren A., Nonclercq D., Bermont L., Refouvelet B., et al. Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells. Bioorg Med Chem 15 (2007) 2269-2282
Lonard D.M., Nawaz Z., Smith C.L., and O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 5 (2000) 939-948